A Phase 1 Study to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects with stable sickle cell disease

$234,770ZIAFY2024HLNIH

National Heart, Lung, And Blood Institute

Investigators

Swee Lay Theincontact

View original record on NIH RePORTER →

A Phase 1 Study to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects with stable sickle cell disease · GrantIndex